Form 4: Maze Therapeutics CSBO Executes Pre-Planned Stock Sale

Maze Therapeutics' Chief Scientific Business Officer, Atul Dandekar, executed a pre-planned sale of common stock following the exercise of options.

Summary

• Atul Dandekar, Chief Scientific Business Officer (CSBO) of Maze Therapeutics, Inc. (MAZE), reported transactions on March 30, 2026.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
• Dandekar exercised stock options to acquire 7,500 shares of common stock at an exercise price of $10.42 per share.
• Concurrently, he disposed of 6,710 shares of common stock at a weighted average price of $29.2556 per share, with individual sales ranging from $28.86 to $29.84.
• An additional 790 shares of common stock were sold at a weighted average price of $30.0173 per share, with individual sales ranging from $29.87 to $30.24.
• Following these transactions, Dandekar beneficially owns 10,503 shares of common stock directly.
• He also beneficially owns 51,643 stock options, which are fully vested as of March 17, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it's an insider sale, it was pre-planned under a 10b5-1 plan, and the sale occurred at a significantly higher price than the option exercise price, indicating a profitable and routine liquidity event for the insider.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and systematic approach to share disposition rather than a reactive sale.
• The sale prices of $29.2556 and $30.0173 per share are significantly higher than the option exercise price of $10.42, indicating a profitable transaction for the insider.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market, though in this context, it represents a routine liquidity event.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common events in the biotechnology and pharmaceutical sectors. These pre-arranged plans allow executives to sell shares systematically over time, managing personal finances while avoiding accusations of trading on material non-public information. Such sales are generally viewed as routine liquidity events rather than signals of management's lack of confidence in the company's future, especially when the sale price is significantly above the exercise price.

Stakeholder Impact

• Shareholders: The sale of shares by a key officer could be perceived as a slight negative, but the pre-planned nature under a 10b5-1 plan mitigates concerns about lack of confidence. The officer still retains significant beneficial ownership in options and common stock.

Key Dates

Recommendation

The filing details a routine, pre-planned insider transaction (exercise of options and subsequent sale of shares) by a Chief Scientific Business Officer. While it's an insider sale, the execution under a Rule 10b5-1 plan and the significant profit realized by the officer (selling at a much higher price than the exercise price) suggest a planned liquidity event rather than a signal of negative company outlook. There is no new fundamental information about the company's operations, financial health, or strategic direction. Therefore, the filing itself does not warrant a change in investment thesis, leading to a 'hold' recommendation.

Keywords

Maze Therapeutics, MAZE, Form 4, Insider Trading, Stock Option Exercise, Stock Sale, Atul Dandekar, 10b5-1 Plan, Beneficial Ownership